Nonrheumatic Systemic Disorders
6 cases on steroid-sparing and disease-modifying therapy decisions in systemic conditions with joint or muscle involvement, and treatment choices at genuine points of diagnostic and evidentiary uncertainty — choose a case below to open its full multi-voice debate.
Renata M., 52, has sarcoidosis that's attacking her joints and muscles rather than her lungs, and needs a first steroid-sparing agent. The disagreement is whether a trial built almost entirely around pulmonary disease has anything real to say about a patient whose lungs are normal.
Josephine R., 66, has kept the same garden for thirty years and is now developing amyloid kidney disease from decades of rheumatoid arthritis. The disagreement over switching drug classes turns out to hinge on one number nobody's checked yet, not on which mechanism sounds more promising.
Dara O., 29, who now drives her widowed father to his own appointments, has had a fourth episode of erythema nodosum with three separate workups turning up nothing. The choice ahead isn't between a proven treatment and an unproven one — it's between two unproven ones, and what actually separates them.
Beatriz N., 58, is in apparent remission from rheumatoid arthritis, but a disease-activity score says otherwise — driven by pain with no synovitis behind it. The disagreement is whether to escalate her arthritis treatment or recognize that the score is measuring something else entirely.
Owen T., 61, a retired cabinetmaker, has newly diagnosed hemochromatosis with early arthritis already showing in his hands. Phlebotomy isn't in question for his overall disease — the real question is whether it does anything for the joints once they've already started to change.
Marguerite S., 67, a new grandmother making long drives just to hold the baby, has had two reproducible episodes of muscle pain on two different statins with no lab evidence either time. The disagreement is what her own two-drug history actually rules out — and it isn't what the room first assumed.